Tradestie Institutional Equity Comparison Engine
ARTV vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ARTV Overall Edge
ARTV Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Artiva Biotherapeutics, Inc. Common Stock (ARTV) driven by superior Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, ARTV trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, ARTV sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
ARTV N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs -62.7%
Momentum & Technical Winner
ARTV
1Y +16.5% vs -77.5% ยท 52W Pos 8% vs 10%
Options & Structure Winner
ARTV
BREAKDOWN (<1st %ile IV) vs BREAKDOWN (N/A IV)
ARTV
NASDAQ
Artiva Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.95
-1.5% 1D
Market Cap
$195.8M
1M Return
-32.48%
1Y Return
+16.52%
Forward P/E
N/M
Unified AI Score
60.0 / 100
BUY
Tech 76.0
Fund 66.0
Flow 69.0
Mom 55.0
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ARTV +16.52%
CVM -77.48%
Spread: +97.52 pp (ARTV Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ARTV Revenue | CVM Revenue | ARTV Op. Margin | CVM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2011 | N/A | $0M | N/A | -1881.0% | CVM |
| FY2012 | N/A | $0M | N/A | -6772.3% | CVM |
| FY2013 | N/A | $0M | N/A | -12450.1% | CVM |
| FY2014 | N/A | $0M | N/A | -9721.4% | CVM |
| FY2023 | $30M | N/A | -93.2% | N/A | ARTV |
| FY2024 | $0M | N/A | -26805.6% | N/A | ARTV |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARTV | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $195.8M | $20.9M | Larger Scale | ARTV |
| Trailing P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -100.0% | -62.7% | Higher Growth | CVM |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -43.6% | -252.5% | Higher ROE | ARTV |
| 52-Week Range Position Momentum | 8% ($3โ$15) | 10% ($1โ$8) | Stronger Trend | CVM |
| Beta / 30D Volatility Risk Regime | 1.71ฮฒ ยท 116% Vol | 0.65ฮฒ ยท 120% Vol | Lower Realized Risk | ARTV |
| Unified Institutional Score Composite Signal | 60.0 / 100 (BUY) | 56.6 / 100 (HOLD) | Higher Composite | ARTV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ARTV vs CVM Buy Guide
ARTV
BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ARTV nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.